|
|
Ferumoxtran-10
enhanced MR in variety of intracranial tumors and other lesions
E.
A. Neuwelt, L. Konyves-Kolonics, M. Haluska
Oregon
Health & Science Univ, Portland, OR
Ultrasmall
particulate iron oxides (USPIO) are used in magnetic resonance imaging (MRI) as
contrast agents due to shortening of T1 and T2 relaxation time.
Ferumoxtran-10 (Combidex), a dextran coated viral sized iron nanoparticle has a
long plasma half-life of 24-30 hours resulting in prolonged and progressive
accumulation in human intracranial lesions.
The distribution, intensity, and time course of MR enhancement with Ferumoxtran
was compared to standard gadolinium (GD) enhanced MR in assessing different
types of intracranial lesions, including malignant tumors, vascular
malformations and demyelinating disorders.
All malignant lesions were histologically proven by surgery or biopsy.
34 studies of 33 patients were analyzed.
All of the patients had a standard brain MR with and without GD.
The dose of Ferumoxtran-10 was 2.6 mg/kg infused intravenously.
The post-iron study includes 24 hours and 48 hours investigations and some
patients also had 3 hours, 6 hours or 72 hours studies.
MR scans included SET1, FST2 and proton density (PD), GRET2*, DWI and EPIT2.
Most lesions detected with GD were also detected with USPIO.
In 6 of 33 patients iron enhanced studies showed a larger area of enhancement
compared to GD.
In 2 patients USPIO showed new areas of enhancement not present on the
gadolinium study.
Regarding the time-course, in 4 patients stronger intensity and larger area of
iron accumulation were detected in consecutive studies consistent with
progressive iron uptake.
In 21 patients no significant differences were detected or GD showed more
intensive enhancement but the same volume of enhancement.
USPIO can add new information on different types of intracranial lesions,
particularly malignant tumors, regarding volume of enhancement, and in some
cases additional lesions can be identified.
© Copyright 2003
American Society of Clinical Oncology All rights
reserved worldwide
Source:
http://www.asco.org/ac/1,1003,_12-002489-00_18-002003-00_19-00104321-00_29-00A,00.asp?cat=CNS+Tumors&parent=
Central+Nervous+System+Tumors&returnpid=2325&SubCat_ID=4
|
